Gilead sets price for COVID-19 drug remdesivir

A typical course of treatment with remdesivir will cost between $2,340 and $3,120 in the U.S., a price range that likely ensures Gilead earns a profit on sales of the drug.

By Ned Pagliarulo • June 29, 2020

Promotional deployment during COVID-19: Quarantine and re-entry

The time is now to shift promotional efforts from live to virtual engagement channels.

June 25, 2020

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Pandemic pushes FDA to 'accelerate' real-world evidence efforts, Hahn says

The agency has grappled with how to use real-world data in regulating drugs and medical devices, but is now leaning on it to update emergency use authorizations, FDA chief Stephen Hahn said.

By Maria Rachal • June 19, 2020

Medical Science Liaisons carry the day with key opinion leaders during the COVID-19 pandemic

Now, more than ever, it's worth investing in Medical Science Liaisons.

By Tonya Broyles and Dave (William) Dawson • June 19, 2020

In FDA 1st, game-based therapeutic gets marketing approval

Digital therapeutics developer Akili won authorization from the agency for a treatment meant to improve attention in children with ADHD.

By Maria Rachal • June 16, 2020

Pressure on generic drugmakers increases with new price fixing lawsuit

The case claims that companies, including Pfizer, Mylan and Novartis, divided the market up into a "fair share" arrangement that allowed them all to raise prices without fearing competition.

By Jonathan Gardner • June 10, 2020

Ex-FDA official slams 'chaos' caused by agency's hands-off approach to antibody tests

Jesse Goodman said the agency's decision to allow developers to self-validate COVID-19 blood assays led to widespread marketing of low-quality tests.

By Nick Paul Taylor • June 10, 2020

Access teams deserve a fresh look during the COVID-19 pandemic

Now, more than ever, it's a good time to rethink your access-staffing model.

By Lisa Blanton, Senior Director, Offering Development, Contract Sales and Medical Solutions, IQVIA • June 8, 2020

Novartis multiple sclerosis drug review delayed by FDA

The Swiss drugmaker now expects a decision on approval by September of ofatumumab, an important drug in its plans to compete with rival Roche. 

By Kristin Jensen • June 3, 2020

CVS sued by Blue Cross plans alleging they were overcharged on generic drugs

BCBS plans in six states contend CVS Health concealed true cash prices for more than a decade. The plans seek to recoup millions of dollars.

By Samantha Liss • May 28, 2020

Medicare telehealth use surged as regulations eased in early weeks of pandemic

CMS is weighing whether to extend telehealth waivers past the scope of the COVID-19 national emergency, agency head Seema Verma has said.

By Rebecca Pifer • May 27, 2020

Trump administration touts plan to limit insulin costs for seniors

Drugmakers Eli Lilly, Novo Nordisk and Sanofi will participate in the voluntary program, which the president rolled out Tuesday in a Rose Garden address.

By Rebecca Pifer • May 26, 2020

Patient engagement in the time of COVID-19

Now, more than ever, it's important to reach patients with information, encouragement, and support.

By Robyn Stoy, Director, Patient Engagement, Contract Sales and Medical Solutions, IQVIA • May 25, 2020

Hospitals, device industry set ground rules for sales reps' return

The guidance expands on advice for resuming elective surgery that a group of medical societies and the American Hospital Association released in April.

By Susan Kelly • May 20, 2020

Hospitals balk as CMS doubles down on price transparency

The draft rule released by CMS Monday would also create a new billing code for CAR-T cancer therapies, which hospitals often lose money on. 

By Shannon Muchmore • May 12, 2020

Pharmas boosted by drug stockpiling, but warn of COVID-19 impact

Patients and wholesalers stocked up on medicines early in 2020, lifting first-quarter sales for many pharmas. But that boost is likely fleeting, disguising the substantial effects the pandemic is having on their businesses.

By Ned Pagliarulo • April 28, 2020

Launch for Neurocrine Parkinson's drug put on hold because of coronavirus

CEO Kevin Gorman told BioPharma Dive it's an inappropriate time to be pitching the drug to neurology doctors, many of who are devoting time to hospitals grappling with COVID-19 cases.

By Jacob Bell • Updated April 27, 2020

COVID-19's impact on pharma marketing

With stay-at-home conditions in effect across most of the country, pharmaceutical marketers are trying to decide how to best manage their marketing investments.

April 23, 2020

Could the coronavirus slow a decades-long shift to value-based care?

As providers struggle with an influx of emergency patients, analysts think they will likely focus on recouping revenue rather than putting more dollars at risk.

By Rebecca Pifer • April 15, 2020

Merck, Samsung join newly crowded market for Herceptin biosimilars

Ontruzant, which will be sold by Merck, is the fifth copycat version of Roche's top-selling breast cancer drug to launch in the U.S.

By Kristin Jensen • April 15, 2020

Doctors say COVID-19 has lowered patient volumes, made finances shaky

A survey of doctors by Piper Sandler found physician practices are deeply impacted by the pandemic, with patient visits down by nearly two-thirds.

By Ron Shinkman • April 13, 2020

Myriad Genetics pulls sales forecast as coronavirus disrupts operations

In response to the spread of COVID-19, Myriad has ended in-office sales calls and begun to collect testing samples directly from patients. 

By Kristin Jensen • April 8, 2020

Amarin shares slump as surprising court defeat puts Vascepa at risk

In what one analyst called a "serious blow," a federal court ruled patents held by Amarin on its heart drug Vascepa were obvious and therefore invalid. 

By Ned Pagliarulo • March 31, 2020

Bristol Myers investors breathe easier as multiple sclerosis drug approved by FDA

Regulatory clearance for Zeposia is the first of three drug approval milestones that must be met for former Celgene shareholders to see the full value of the 2019 acquisition.

By Jonathan Gardner • March 26, 2020

Coronavirus forces ASCO, cancer research's top meeting, to move online

State governments, including ASCO's host state of Illinois, are calling for residents to stay home, making the prospect of holding a meeting that draws thousands untenable.

By Ned Pagliarulo • March 24, 2020